Descending pain inhibitory pathway

The **descending pain inhibitory pathway** is a neural network composed of multiple neuronal projections that originate in higher brain centers—including the periaqueductal gray (PAG), the nucleus raphe magnus (NRM, rich in serotonin/5-HT), and the locus coeruleus (LC, rich in noradrenaline/NA)—and terminate in the dorsal horn of the spinal cord[2][3][7]. This pathway regulates the transmission of nociceptive (pain) signals by releasing neurotransmitters (notably serotonin and norepinephrine), which in turn modulate spinal cord neurons and interneurons to suppress pain[1][2][3][4][7]. The system is engaged by both endogenous opioids and exogenous drugs (such as morphine, clonidine, duloxetine, and other opioids or monoamine reuptake inhibitors), but it is not a single receptor, enzyme, or protein. Dysfunction or impaired engagement of this pathway is linked to chronic pain conditions and decreased analgesic efficacy[1][4][5][7]. **Further clarification and rationale**: - *Is it a molecular target?* No. The descending pain inhibitory pathway is a complex system involving neurotransmitters, various receptors (such as opioid, serotonin, and adrenergic receptors), and multiple anatomical structures—not a single molecule, receptor, or protein[1][2][3][4][7]. - *Drug interactions/mechanisms:* Drugs like morphine, clonidine, duloxetine, and tricyclic antidepressants indirectly act through this pathway by enhancing endogenous inhibition of pain via 5-HT (serotonin), NA (noradrenaline), and opioid signaling, but their primary targets are the classical receptors (mu-opioid receptor, alpha-2 adrenergic receptor, serotonin receptors, etc.)[1][3][4][7]. - *Implications for drug discovery/annotation databases:* Curation of the "descending pain inhibitory pathway" as a molecular target is incorrect—it should instead be described as a functional or anatomical system. If a single, actionable molecular target within this pathway is needed, refer instead to specific constituents such as **mu-opioid receptor**, **alpha-2 adrenergic receptor**, or **serotonin receptor subtypes** (e.g., 5-HT1A, 5-HT2A), all of which are established drug targets[1][3][4].

Other names

Descending pain modulatory systemdescending pain control pathwaydescending inhibitory controldescending analgesic pathway